tbuckley/cabot-search huggingface dataset:
Atypical Antipsychotic Drugs, Dementia, and Risk of Death
Authors: Harminder Sikand, Joyce Jaojoco, Leslie Linares, Paul S. Phillips
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I trial of imexon, Inj. plus gemcitabine in patients with advanced previously untreated pancreatic adenocarcinoma
Authors: S. J. Cohen, M. Zalupski, M. Modiano, P. Conkling, D. Mahadevan, L. Wong, D. Smith, R. T. Dorr, M. Boytim, E. M. Hersh
Journal: Journal of Clinical Oncology (2007)

15058 Background: Imexon for inj. (Amplimexon®, AMP) is an aziridine-containing iminopyrrolidone which causes G2 arrest, accumulation of reactive oxygen species, and induction of apoptosis in pancreatic cancer cells. AMP demonstrated synergy with gemcitabine (GEM) in preclinical pancreatic cancer models. This phase I study of AMP plus GEM was undertaken to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT). Secondary endpoints were pharmacokinetics for both agents (PK) and tumor response. Methods: Patients (pts) with previously untreated advanced pancreatic adenocarcinoma received one of two dosing regimens. The first 19 received 30 minute AMP IV days 1–5 and 15–19 followed by 30 minute GEM IV days 1, 8 and 15 Q4 wks (Regimen A). Dosing was modified after 19 pts to administer both AMP and GEM over 30 minutes days 1, 8 and 15 every 4 weeks (Regimen B). Dose levels (AMP/GEM, in mg/m 2 ) for Regimen A: 200/800, 280/800, 200/1000, and 280/1000, and for Regimen B: 280/1000, 335/1000, 390/1000, 540/1000, and 750/1000. The current cohort is 1000/1000. Pts were assessed for response after cycles 2, 5 and 8. PK and pharmacodynamic (plasma thiol depletion) measurements were obtained during cycle one. Results: Forty-six pts have been treated to date, with 36 having complete toxicity data and evaluable. Pt characteristics: M/F (24/12), Age (mean 60.4 years, range 43–75), ECOG PS 0/1 (56%, 44%), metastatic/locally advanced (91%, 9%). The 36 pts have completed 122.5 cycles of therapy (median 2, range 0.5–12). Common toxicities: anemia (77%), fatigue (71%), nausea (60%), fever (54%), and leukopenia (54%). DLT were 1/6 at 280/1000 (Regimen A - febrile neutropenia), 1/6 at 280/1000 (Regimen B - gr 3 hypotension, gr 4 renal failure), and 1/9 at 390/1000 (gr 3 hyperbilirubinemia). Accrual continues at 1000/1000. Of 36 pts, 4 have had partial responses and 14 stable disease. PK and plasma thiol analysis are ongoing. Conclusions: Imexon can be administered safely with full dose gemcitabine. Accrual continues to define the combination MTD. The response rate in this phase I study compares favorably with historical gemcitabine monotherapy, and further phase II evaluation of this combination in advanced pancreatic cancer is warranted. No significant financial relationships to disclose.
DNA-microarrays predicting chemotherapy response of ovarian carcinomas
Authors: Manfred Dietel, Carsten Denkert, Jan Budczies, Balázs Györffy, Hermann Lage
Journal: Clinical Cancer Research (2006)

B62  Introduction. Drug resistance remains a major problem in therapy of systemic cancer diseases. Due to the high potency to adapt to therapeutical approaches, malignant tumour cells frequently develop escape mechanisms in response to anti-cancer drugs.Cell culture experiments. To define resistance associated signatures for common cytostatics we tested 30 cancer cell lines for sensitivity to 5-FU, cisplatin, cyclophosphamide, doxorubicin, etoposide, methotrexate, mitomycin C, mitoxantrone, paclitaxel, topotecan and vinblastine at drug concentrations achievable in vivo. The resistance index defined previously was applied to designate the cell lines as sensitive or resistant, then, the subset of resistant versus sensitive cell lines for each drug was compared. Expression signatures for all cell lines were obtained by interrogating Affymetrix U133A arrays. Prediction Analysis of Microarrays was applied for feature selection.Prediction profiles for the resistance against each chemotherapy agent were constructed, containing 42 to 297 genes. The overall accuracy of the predictions in a leave-one-out cross validation was 86%. A list of the top 67 MDR candidate genes associated with resistance against at least 4 anticancer agents was identified. Moreover, the differential expressions of 46 selected genes were also measured by quantitative RT-PCR using a TaqMan micro fluidic card system. Association with resistance were detected for 76 genes.Preclinical studies targeted to ovarian cancer. We tested 44 ovarian cancer specimens with known clinical follow up to predict platinum and paclitaxel resistance. On the basis of patterns with 5 up to 100 altered gene expressions preliminary results on the clinical specimens gave a positive predictive value between 70-80% regarding response to the carboplatin-paclitaxel combination regime.Conclusion. The gene expression profiling thus can be helpful for the pre-treatment assessment of anti-cancer therapy of ovarian carcinomas. Although clinical studies still have to be conducted, it might become possible to discriminate between responders and non-responders prior to therapy allowing an individualized strategy with a personalized combination of drugs.
Abstract 17968: The New St. Jude TrifectaTM Versus Carpentier-Edwards Perimount MagnaTM and Magna EaseTM Aortic Bioprosthesis: Is There a Hemodynamic Superiority?
Authors: Daniel Wendt, Jorg Assmann, Bjorn Plicht, Jan Boehm, Susanne Pasa, Thomas Buck, Jarowit Piotrowski, Markus Neuhaeuser, Raimund Erbel, Heinz Jakob, Matthias Thielmann
Journal: Circulation (2012)

Background: The TrifectaTM valve is a new bovine pericardial aortic bioprosthesis designed for supra-annular aortic valve replacement (AVR). We compared the hemodynamic performance of the TrifectaT...
Y chromosome sequence variation and the history of human populations
Authors: Peter A. Underhill, Peidong Shen, Alice A. Lin, Li Jin, Giuseppe Passarino, Wei H. Yang, Erin Kauffman, Batsheva Bonné-Tamir, Jaume Bertranpetit, Paolo Francalacci, Muntaser Ibrahim, Trefor Jenkins, Judith R. Kidd, S. Qasim Mehdi, Mark T. Seielstad, R. Spencer Wells, Alberto Piazza, Ronald W. Davis, Marcus W. Feldman, L. Luca Cavalli-Sforza, Peter. J. Oefner
Journal: Nature Genetics (2000)
Influence of Aqueous Cream BP on corneocyte size, maturity, skin protease activity, protein content and transepidermal water loss
Authors: D. Mohammed, P.J. Matts, J. Hadgraft, M.E. Lane
Journal: British Journal of Dermatology (2011)

Aqueous Cream BP is frequently prescribed for patients with eczema and is known to induce sensitivity in certain patients and also to decrease the thickness of the stratum corneum (SC). We have previously reported methodology to quantify corneocyte maturity and size, protease activity and protein content within different levels of the SC.The aim of the present study was to investigate changes in corneocyte size, corneocyte maturity, selected protease activities, protein content and transepidermal water loss (TEWL) in normal skin after a 28-day application of Aqueous Cream BP.The left and right mid volar forearms of six healthy female volunteers were selected as the study sites. Aqueous Cream BP was applied twice daily to treated sites for 28 days. At the end of this period, the site was tape-stripped and corneocyte maturity, corneocyte size and protease activity of the desquamatory kallikrein proteases, KLK5 and KLK7, and the inflammatory proteases tryptase and plasmin were measured. Protein content and TEWL measurements were also recorded.Corneocyte maturity and size decreased with increasing number of tape strips, and were significantly lower in treated sites compared with untreated sites. Protease activity and TEWL values were higher (P < 0·05) for the treated sites compared with untreated sites. The amount of protein removed from deeper layers of treated sites was significantly lower than from untreated sites.We report rapid minimally invasive measures of the effects of Aqueous Cream BP at the cellular and molecular level of the skin. Treatment with this formulation is associated with increased desquamatory and inflammatory protease activity. Changes in corneocyte maturity and size are also indicative of accelerated skin turnover induced by chronic application of this emollient. These findings question firmly the routine prescription of this preparation as a moisturizer in patients with atopic dermatitis.
Infection sporadique causée par une souche d'Escherichia coli O157 entérohémorragique
Authors: F Allerberger, L Beutin, T Cheasty, G Gonedera, H Karch
Journal: Eurosurveillance (1999)

En 1997, le Ministere de la sante autrichien a cree, au sein du Laboratoire de sante publique federal d‘Innsbruck, un laboratoire de reference des souches Escherichia coli enterohemorrhagiques. Ce laboratoire de reference est charge de rechercher les sources d‘infections responsables d‘intoxications alimentaires afin d‘eviter d‘autres epidemies. Si cela s'avere necessaire, ces enquetes sont menees en collaboration avec le Reseau Europeen pour la surveillance epidemiologique et le controle des maladies transmissibles, projet de l‘Union Europeenne (UE). Cet article decrit un exemple specifique d‘une telle collaboration europeenne.
Sigma‐2 Receptor Ligands and Their Perspectives in Cancer Diagnosis and Therapy
Authors: Yun‐Sheng Huang, He‐Lin Lu, Lang‐Jun Zhang, Zongwen Wu
Journal: Medicinal Research Reviews (2013)

Abstract The sigma‐2 receptor is highly expressed in various rapidly proliferating cancer cells and regarded as a cancer cell biomarker. Selective sigma‐2 ligands have been shown to specifically label the tumor sites, induce cancer cells to undergo apoptosis, and inhibit tumor growth. Sigma‐2 ligands are potentially useful as cancer diagnostics, anticancer therapeutics, or adjuvant anticancer treatment agents. However, both the cloning of this receptor and the identification of its endogenous ligand have not been successful, and the lack of structural information has severely hindered the understanding of its physiological roles, its signaling pathways, and the development of more selective sigma‐2 ligands. Recent data have implicated that sigma‐2 binding sites are within the lipid rafts and that PGRMC1 (progesterone receptor membrane component 1) complex and sigma‐2 receptor may be coupled with EGFR (epidermal growth factor receptor), mTOR (mammalian target of rapamycin), caspases, and ion channels. Due to its promising applications in cancer management, there are rapidly increasing research efforts that are being directed into this field. This review article updates the current understanding of sigma‐2 receptor and its potential physiological roles, applications, interaction with other effectors, with special focuses on the development of sigma‐2 ligands, their chemical structures, pharmacological profiles, applications in imaging and anticancer therapy.
Stimulated Growth of Syngeneic Tumors at the Site of an Ongoing Delayed-Hypersensitivity Reaction to Tuberculin in BALB/c Mice
Authors: Meera S. Paranjpe, Charles W. Boone
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Stimulated Growth of Syngeneic Tumors at the Site of an Ongoing Delayed-Hypersensitivity Reaction to Tuberculin in BALB/c Mice Get access Meera S. Paranjpe, Meera S. Paranjpe Search for other works by this author on: Oxford Academic PubMed Google Scholar Charles W. Boone Charles W. Boone Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 4, April 1974, Pages 1297–1299, https://doi.org/10.1093/jnci/52.4.1297 Published: 01 April 1974 Article history Received: 26 October 1973 Accepted: 14 December 1973 Published: 01 April 1974
Alzheimer Study to Recruit Patients
Authors: Tracy Hampton
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Breast Cancer Cell–Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes
Authors: Cristina Ghirelli, Fabien Reyal, Marine Jeanmougin, Raphaël Zollinger, Philémon Sirven, Paula Michea, Christophe Caux, Nathalie Bendriss-Vermare, Marie-Hélène Donnadieu, Martial Caly, Virginie Fourchotte, Anne Vincent-Salomon, Brigitte Sigal-Zafrani, Xavier Sastre-Garau, Vassili Soumelis
Journal: Cancer Research (2015)

Reciprocal interactions between tumor cells and their microenvironment vitally impact tumor progression. In this study, we show that GM-CSF produced by primary breast tumor cells induced the activation of plasmacytoid predendritic cells (pDC), a cell type critical to anti-viral immunity. pDC that expressed the GM-CSF receptor were increased in breast tumors compared with noninvolved adjacent breast tissue. Tumor-activated pDC acquired naïve CD4(+) T-cell stimulatory capacity and promoted a regulatory Th2 response. Finally, the concomitant increase of GM-CSF and pDC was significantly associated with relatively more aggressive breast cancer subtypes. Our results characterize the first tumor-derived factor that can activate pDC to promote a regulatory Th2 response, with implications for therapeutic targeting of a tumor-immune axis of growing recognition in its significance to cancer.
Abstract 20372: High-Mobility Group Box-1 Activates Toll-Like Receptor 4: A Potential Novel Mechanism in Endothelial Dysfunction in Diabetes Mellitus
Authors: Maria Alicia Carrillo-Sepulveda, R. Clinton Webb
Journal: Circulation (2014)

Background:  Macro and microvascular complications are the main problem of all forms of diabetes mellitus. Endothelial dysfunction plays a key role in the pathogenesis of vascular complications, and most anti-diabetic drugs still do not avoid the development of endothelial dysfunction. Recent evidence shows that diabetic patients have increased serum high-mobility group box-1 (HMGB1) levels and upregulation of Toll-like receptor 4 (TLR4), a key component of innate immunity; however whether HMGB-1 is linked with TLR4 and it has impact in diabetic endothelial dysfunction is unknown. We hypothesize that HMGB1 activates TLR4 in endothelial cells (EC), which in turn increases generation of reactive oxygen species (ROS) and reduces NO bioavailability thereby causing endothelial dysfunction.   Methods:  Human EC were treated with recombinant 200ng/mL HMGB1 for 24 hours and intracellular ROS were detected by H2DCF-DA fluorescence and protein expression of MyD88, a downstream adaptor of TLR4 signaling, was measured by immunoblotting. Diabetes was induced in wild-type (WT) and knockout (KO) TLR4 -/- mice by streptozotocin (STZ) (50mg/kg; 5 weeks) treatment and ROS levels were determined in blood vessel segments. Endothelial function was assessed in mesenteric arteries from STZ-induced diabetic rats treated with 50ug/day CLI095, an inhibitor of TLR4, over 14 days using a wire myograph.   Results:  HMGB1 reduced phosphorylated eNOS levels (0.8 fold, p   Conclusions:  Our data suggest that TLR4 signaling plays role in the diabetic endothelial dysfunction via increased ROS levels and implies HMGB1 as a novel trigger of endothelial dysfunction in diabetes through TLR4 signaling.
SURGICAL THERAPY FOR CHRONIC NONSPECIFIC PNEUMONITIS
Authors: W R DEATON
Journal: Annals of Internal Medicine (1958)

Article1 June 1958SURGICAL THERAPY FOR CHRONIC NONSPECIFIC PNEUMONITISW. RALPH DEATON JR., M.D.W. RALPH DEATON JR., M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-48-6-1289 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn 1948 Kershner and Adams4introduced the term "chronic nonspecific pneumonitis" to describe a definite pulmonary lesion that had several characteristics. Clinically, this lesion provoked a febrile illness with an insidious onset, chronic course, productive cough, pleuritic pain, and occasionally hemoptysis. Pathologically, the involved area, usually limited to a lobe, was heavy and fibrotic. Microscopic examination showed intralobular and interalveolar fibrosis, thickening of the alveolar walls, lymphoid and plasma cell hyperplasia, redundance of the bronchial mucosa, chronic atelectasis, and hemorrhagic and purulent alveolar exudate. Kershner and Adams reported on the surgical treatment of 10 such cases, all of whom had...Bibliography1. AsheMcDonaldClagett WMJROT: Nonspecific pneumonitis of the left upper lobe (simulating the "middle lobe syndrome" and producing an early superior pulmonary sulcus syndrome), J. Thoracic Surg. 21: 1-6, 1951. CrossrefGoogle Scholar2. BrewerJonesDolley LAWMFS: Non-malignant intrathoracic lesions simulating bronchogenic carcinoma, J. Thoracic Surg. 17: 439-463, 1948. CrossrefGoogle Scholar3. DavisPeabodyKatz EWJWS: The solitary pulmonary nodule, J. Thoracic Surg. 32: 728-771, 1956. CrossrefGoogle Scholar4. KershnerAdams RDWE: Chronic nonspecific suppurative pneumonitis, J. Thoracic Surg. 17: 495-513, 1948. CrossrefGoogle Scholar5. MacQuigg RE: Abronchiectatic bronchiectasis: the recognition of surgical pneumonitis, Am. J. Surg. 22: 465-473, 1956. Google Scholar6. WaddellSniffenSweet WRRCRH: Chronic pneumonitis: its clinical and pathologic importance, J. Thoracic Surg. 18: 707-737, 1949. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Greensboro, North Carolina*Received for publication May 3, 1957.From The Department of Surgery, The Moses H. Cone Memorial Hospital, Greensboro, North Carolina.Requests for reprints should be addressed to W. Ralph Deaton, Jr., M.D., 1027 Professional Village, Greensboro, North Carolina. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1958Volume 48, Issue 6Page: 1289-1299KeywordsAntibioticsBronchiectasisBronchitisChronic bronchitisFibrosisLesionsMucous membranesPlasma cellsPneumonitisSurgery Issue Published: 1 June 1958 PDF DownloadLoading ...
Minimal Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Authors: W. Zeijlemaker, G.J. Schuurhuis
Journal: Leukemia (2013)

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. With current treatment strategies, almost 80% of AML patients (18-60 years) will achieve com‐ plete remission (CR). However, approximately 50% of these patients will experience a re‐ lapse, resulting in a five-year survival rate of only 35%-40% [1]. This implies that despite CR, in these patients a number of cancer cells survive treatment and can grow out to cause a re‐ lapse. Efforts towards development of more sensitive methods to accurately determine CR and detect residual cancer cells are necessary to improve risk-adapted management to even‐ tually prolong overall survival rates.
398. Transduction of Human Hematopoietic Stem Cells and T-Lymphocytes with RD114-TR-Pseudotyped Lentiviral Vectors
Authors: Francesca Di Nunzio, Bianca Piovani, Sabrina Cazzaniga, Chiara Bonini, Francois-Loic Cosset, Fulvio Mavilio, Anna Stornaiuolo
Journal: Molecular Therapy (2004)
Sentinel node biopsy in breast cancer
Authors: M. Dixon
Journal: BMJ (1998)

The status of the axillary lymph nodes in a woman with breast cancer is the single most important prognostic factor, and important clinical decisions are based on it. In the absence of non-invasive methods, it has become routine either to perform a partial axillary dissection to stage the axilla or to remove completely all axillary lymph nodes to both stage and treat the axilla. With the development of screening, increasing numbers of women are seen who are node negative. In these patients extensive axillary surgery is difficult to justify because most women gain no significant benefit and suffer considerable morbidity from the axillary surgery. Research has focused on developing procedures that assess axillary lymph node status while minimising morbidity.

Twenty years ago Cabanas showed the existence of a specific draining lymph node, the so called “sentinel” lymph node, which could be identified after lymphangiography through the dorsal lymphatics of the …
749. Adeno-Associated Virus Vectors Integrate at Chromosome Breakage Sites
Authors: Daniel G. Miller, Lisa M. Petek, David W. Russell
Journal: Molecular Therapy (2004)

Adeno-associated virus (AAV) vectors transduce cells by multiple pathways, including integration at non-homologous chromosomal locations by an unknown mechanism that does not require viral proteins. We reasoned that spontaneous chromosome breaks may facilitate vector integration and investigated this by transducing cells containing a specific chromosomal double strand break created by the endonuclease I-SceI. Vector proviruses were frequently found at I-SceI cleavage sites, and sequencing of vector:chromosome junctions revealed micro-homologies, deletions, and insertions that in some cases could be explained by template-directed DNA synthesis prior to ligation. Similar junctions were observed when integration occurred at random locations, and infection with AAV vectors did not increase mutation rates in normal human cells. Our results establish a mechanism for integration, and suggest that AAV vectors integrate at existing chromosome breaks rather than causing breaks, a finding that has unique implications regarding their clinical use.